Scientists believe that air pollution could be a major cause behind the rise in global lung cancer cases in people that have ...

released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).

for non-small cell lung cancer (NSCLC). As the company progresses through critical clinical trials and approaches potential commercialization, investors and analysts are closely watching its ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

As the company continues to advance its innovative approaches to pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC ... with the stock showing significant momentum ...

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

( MENAFN - GlobeNewsWire - Nasdaq) Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Experts have analyzed data to discover why non-smokers are developing lung cancer, and it is down to air pollution in our ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...